News summarySEC EDGARNov 9, 2026, 12:00 PM
Editas Medicine, 8-K (2.02, 9.01): reported results of operations
Editas reported $190.2 million in cash and securities and a runway into the second half of 2028, progress toward starting its EDIT-401 Phase 1/2 study, and a milestone payment triggered by acceptance of a second Bristol Myers Squibb collaboration IND/CTA.